Abstract
Background: Statins are a well-established class of drugs in both preventing coronary events and treating cardiovascular atherosclerotic disease, however their use in heart failure is still in debate.
Objectives: To establish whether statins' pleiotropic actions in endothelium, inflammation, remodeling of the heart and anti-arrhythmic potential may be in favorable of heart failure patients.
Methods: We proceed to literature search of English bibliography under the terms heart failure, statins, 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Results: Various experimental and clinical trials on the use of statins in the different subtypes of heart failure according to the ejection fraction of the left ventricle have been conducted to conclude whether statins should be part of their patients' treatment. The evidence shows that the subgroup of patients with ischemic heart disease and those with preserved ejection fraction seems to have better results from the use of statins although randomized control trial in the total heart failure population did not show any benefit in mortality.
Conclusion: Statins may be beneficial to left ventricle systolic and diastolic performance of heart failure patients however their result in mortality cannot be established based on current evidence.
Keywords: Statins, heart failure, left ventricle ejection fraction, left ventricle remodeling, dyslipidemia, pleiotropic effects.
Current Pharmaceutical Design
Title:Statins and Left Ventricular Function
Volume: 23 Issue: 46
Author(s): Agamemnon Bakakos, Evangelos Oikonomou*, Georgia Vogiatzi, Gerasimos Siasos, Sotiris Tsalamandris, Alexios Antonopoulos, Costas Mourouzis, Petros Fountoulakis, Manolis Vavuranakis and Dimitris Tousoulis
Affiliation:
- 1st Department of Cardiology, ‘Hippokration' Hospital, University of Athens Medical School, Athens,Greece
Keywords: Statins, heart failure, left ventricle ejection fraction, left ventricle remodeling, dyslipidemia, pleiotropic effects.
Abstract: Background: Statins are a well-established class of drugs in both preventing coronary events and treating cardiovascular atherosclerotic disease, however their use in heart failure is still in debate.
Objectives: To establish whether statins' pleiotropic actions in endothelium, inflammation, remodeling of the heart and anti-arrhythmic potential may be in favorable of heart failure patients.
Methods: We proceed to literature search of English bibliography under the terms heart failure, statins, 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Results: Various experimental and clinical trials on the use of statins in the different subtypes of heart failure according to the ejection fraction of the left ventricle have been conducted to conclude whether statins should be part of their patients' treatment. The evidence shows that the subgroup of patients with ischemic heart disease and those with preserved ejection fraction seems to have better results from the use of statins although randomized control trial in the total heart failure population did not show any benefit in mortality.
Conclusion: Statins may be beneficial to left ventricle systolic and diastolic performance of heart failure patients however their result in mortality cannot be established based on current evidence.
Export Options
About this article
Cite this article as:
Bakakos Agamemnon, Oikonomou Evangelos*, Vogiatzi Georgia, Siasos Gerasimos , Tsalamandris Sotiris, Antonopoulos Alexios , Mourouzis Costas, Fountoulakis Petros , Vavuranakis Manolis and Tousoulis Dimitris , Statins and Left Ventricular Function, Current Pharmaceutical Design 2017; 23 (46) . https://dx.doi.org/10.2174/1381612823666170926125754
DOI https://dx.doi.org/10.2174/1381612823666170926125754 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Mobile Phone Based Biomedical Imaging Technology: A Newly Emerging Area
Recent Patents on Biomedical Engineering (Discontinued) Editorial [Hot topic: Cardioembolic Infarction: A Renewed Topic of Interest (Guest Editor: Adria Arboix)]
Current Cardiology Reviews Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
Current Pharmaceutical Design Overcoming Barriers to Evidence-Based Diabetes Care
Current Diabetes Reviews Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Polyphenols from Red Wine Modulate Immune Responsiveness: Biological and Clinical Significance
Current Pharmaceutical Design The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design